Xuanzhubio-b
2575
Rank in Stocks
#11541
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
Share Price
$1.07
Last synced: 2026-11-10
Market Cap
$555.11M
Change (1 day)
1.51%
Change (1 year)
-87.01%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Xuanzhubio-b (2575)
Category
Healthcare
Operating Margin for Xuanzhubio-b (2575)
Operating Margin as of November 2026 TTM: -182.18%
According to Xuanzhubio-b's latest financial reports, its current operating margin (TTM) is -182.18%. At the end of 2025 the company had an operating margin of -450.85%.
Operating Margin history for Xuanzhubio-b from 2022 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -182.18% | -59.59% |
| 2025 | -450.85% | -75.93% |
| 2024 | -1,873.40% | -99.84% |
| 2023 | -1,169,368.85% | 0.00% |
| 2022 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.11% |
DE
|
|
| 19.68% | -100.11% |
DE
|
|
| 13.26% | -100.07% |
JP
|
|
| 17.08% | -100.09% |
CH
|
|
| 14.92% | -100.08% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Xuanzhubio-b's operating margin
What is Xuanzhubio-b's operating margin?
Xuanzhubio-b's operating margin is -182.18%, as of Nov 2026.
What was Xuanzhubio-b's operating margin in 2025?
In 2025, Xuanzhubio-b's operating margin was -450.85%, compared with -1,873.40% in 2024.
How has Xuanzhubio-b's operating margin changed since 2022?
From 2022 to 2025, Xuanzhubio-b's operating margin was highest in 2022 (0.00%) and lowest in 2023 (-1,169,368.85%).
How does Xuanzhubio-b's operating margin compare with similar companies?
Xuanzhubio-b's operating margin (-182.18%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.